GlassScriptPhysician profile
Morgan Poston
NPI 1740800903
$9,679.68
in general payments reported to CMS, 2019-2025
32 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,104 · 2022: $3,909 · 2023: $3,321 · 2024: $902 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,666.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,589.14 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,130.14 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $681.58 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $659.59 | 2021-2024 | Uzedy, Austedo Xr |
| Alkermes, INC. | $643.34 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $561.34 | 2021-2025 | Rexulti, Vyepti |
| Neurocrine Biosciences, INC. | $558.03 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $486.25 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $332.42 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $302.92 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $294.99 | 2021-2024 | Trintellix |
| Corium, LLC | $289.00 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $250.43 | 2021-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $248.66 | 2022-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $242.64 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $215.35 | 2022-2024 | Sunosi, Auvelity |
| Ironshore Pharmaceuticals INC. | $215.34 | 2022-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $142.68 | 2021-2022 | |
| Indivior INC. | $138.73 | 2022-2024 | Sublocade |
| Neos Therapeutics, LP | $120.56 | 2021-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $108.14 | 2022-2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $98.71 | 2021-2023 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $94.45 | 2022-2023 | Belsomra |
| Amgen INC. | $83.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.77 | 2024-2025 | Cobenfy |
| Eisai INC. | $30.02 | 2021 | |
| Almatica Pharma LLC | $22.68 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.44 | 2023 | Belbuca |
| Hikma Pharmaceuticals USA | $21.85 | 2022 | |
| Sage Therapeutics, LLC | $21.57 | 2022 | |
| Livanova USA, INC. | $17.19 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Brainsway USA INC | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Poston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.